AI is ready to take on a massive healthcare challenge

Reaching a mammoth financial concern of $966 billion in 2019, the cost of uncommon diseases far surpassed diabetes ($ 327 billion), cancer ($ 174 billion), heart illness ($ 214 billion) and other persistent illness.

Jointly, there are thousands of uncommon illness and those affect around 400 million individuals worldwide. About half of uncommon disease clients are children, and the common client, old or young, weather a diagnostic odyssey lasting five years or more during which they go through many tests and see many professionals before ultimately receiving a medical diagnosis.
No longer a moonshot obstacle
Shortening that diagnostic odyssey and decreasing the associated costs was, until just recently, a moonshot obstacle, however is now within reach. About 80% of rare diseases are hereditary, and innovation and AI advances are combining to make hereditary screening commonly accessible.
Whole-genome sequencing, an advanced hereditary test that allows us to examine the whole human DNA, now costs under $1,000, and market leader Illumina is targeting a $100 genome in the future.
The staying obstacle is translating that information in the context of human health, which is not an unimportant difficulty. The common human includes 5 million distinct genetic variations and of those we need to identify a single disease-causing variation. Current advances in cognitive AI allow us to interrogate an individuals entire genome series and identify disease-causing mechanisms instantly, enhancing human capacity.
A shift from narrow to cognitive AI
The path to a broadly usable AI service required a paradigm shift from narrow to wider machine learning designs. Researchers analyzing genomic information evaluate thousands of information points, gathered from various sources, in various formats.
An analysis of a human genome can take as long as eight hours, and there are just a couple of thousand qualified scientists worldwide. Experts are expecting 50 million-60 million people will have their DNA sequenced every year when we reach the $100 genome. How will we evaluate the information produced in the context of their health? Thats where cognitive intelligence can be found in.

Einat Metzer is CEO and co-founder of Emedgene, a leading accuracy medicine intelligence company.

Cognitive intelligence, or cognitive computing services, blend artificial intelligence innovations like neural networks, device knowing, and natural language processing, and are able to simulate human intelligence.

By meaning, an uncommon disease impacts less than 200,000 individuals. Collectively, there are thousands of unusual diseases and those affect around 400 million individuals worldwide. About half of rare disease patients are kids, and the normal patient, old or young, weather a diagnostic odyssey lasting five years or more throughout which they undergo numerous tests and see many professionals before eventually getting a diagnosis.

Which disease results in the highest overall financial concern per year? If you guessed diabetes, cancer, heart problem or even weight problems, you thought wrong. Reaching a mammoth monetary problem of $966 billion in 2019, the cost of uncommon illness far outmatched diabetes ($ 327 billion), cancer ($ 174 billion), heart disease ($ 214 billion) and other chronic diseases.